DexCom price target lowered to $90 from $92 at Barclays

Barclays analyst Matt Miksic lowered the firm’s price target on DexCom (DXCM) to $90 from $92 and keeps an Equal Weight rating on the shares. The company’s final Q4 results and outlook were consistent with the January pre-release, requiring reduced 2025 numbers to be in-line with guidance, the analyst tells investors in a research note.